 Tiziana Life Sciences Ltd NASDAQ:TLSA has announced the Investigational New Drug IND application filing for its milciclib treatment in combination with gemcitabine for non-small cell lung cancer NSCLC. The company said the Phase 2 IND filing, which was achieved with minimal additional resource deployment, enhances the asset value and its optionality for milciclib. 